Antimicrobial and Controlled Release Studies of a Novel Nystatin Conjugated Iron Oxide Nanocomposite

Table 2

Percentage inhibition of nystatin chitosan magnetic nanocomposite against different microorganisms.

Sample	Concentration	Percentage inhibition (Mean ± SEM)
		Staphylococccus aureus	Pseudomonas aeruginosa	Escherichia coli	Candida albicans
Nys-CS-MNP	1 mg	−10.236 ± 1.821	99.014 ± 0.081	25.771 ± 0.498	93.750 ± 0.125
Nys-CS-MNP	2 mg	1.312 ± 0.000	99.085 ± 0.000	35.075 ± 0.431	99.957 ± 0.025
CS	1 mg	−4.987 ± 0.000	23.994 ± 0.814	32.313 ± 0.431	11.638 ± 1.246
CS	2 mg	−7.087 ± 1.821	22.535 ± 4.071	28.761 ± 0.431	14.828 ± 0.000
MNPs	1 mg	0.787 ± 0.910	−19.718 ± 0.814	25.373 ± 4.314	13.362 ± 0.249
MNPs	2 mg	−2.887 ± 0.000	−4.676 ± 1.889	26.866 ± 0.000	13.793 ± 12.458
CS-MNP	1 mg	2.887 ± 0.000	−7.042 ± 0.814	16.418 ± 4.314	14.828 ± 0.000
CS-MNP	2 mg	22.835 ± 0.910	1.268 ± 0.081	24.627 ± 4.314	14.267 ± 0.000